Skip to main content
  1. Home
  2. Doctor Thomas Hartung

Doctor Thomas Hartung

Toward a Deeper Understanding


Leading a revolution in toxicological approaches

Thomas Hartung, Professor of Evidence-Based Toxicology at Johns Hopkins University, is helping increase the implementation of omics-focused approaches toward a deeper understanding of toxicology.

Current toxicological processes and approaches face a variety of challenges and limitations. Methods are often not productive enough or too costly, meaning they cannot be used sustainably, and there is sometimes an over-reliance on animal testing. The current regulations on certain toxicological processes are also highly precautionary; using today's rules, it would be difficult to bring something like aspirin to market, for example. Additionally, the proliferation of new products and treatments from other areas demands new toxicological approaches.

 Professor Thomas Hartung

Director, Center for Alternative to Animal Testing (CAAT)
Johns Hopkins Bloomberg School of Public Health

Selected publications

3S - Systematic, systemic, and systems biology and toxicology.
Smirnova L, Kleinstreuer N, Corvi R, Levchenko A, Fitzpatrick SC, Hartung T.
ALTEX. 2018;35(2):139-162. doi: 10.14573/altex.1804051.

Metabolomic network analysis of estrogen-stimulated MCF-7 cells: a comparison of overrepresentation analysis, quantitative enrichment analysis and pathway analysis versus metabolite network analysis.
Maertens A, Bouhifd M, Zhao L, Odwin-DaCosta S, Kleensang A, Yager JD, Hartung T.
Arch Toxicol. 2017 Jan;91(1):217-230. doi: 10.1007/s00204-016-1695-x.

Information-dependent enrichment analysis reveals time-dependent transcriptional regulation of the estrogen pathway of toxicity.
Pendse SN, Maertens A, Rosenberg M, Roy D, Fasani RA, Vantangoli MM, Madnick SJ, Boekelheide K, Fornace AJ, Odwin SA, Yager JD, Hartung T, Andersen ME, McMullen PD.
Arch Toxicol. 2017 Apr;91(4):1749-1762. doi: 10.1007/s00204-016-1824-6.

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, Neisser M, Nguyen C, Lee R, Park JK, Reyes J, Hartung T, Rojas C, Rais R, Tsukamoto T, Semenza GL, Hanes J, Slusher BS, Le A.
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36. doi: 10.1073/pnas.1611406113.

The human toxome project.
Bouhifd M, Andersen ME, Baghdikian C, Boekelheide K, Crofton KM, Fornace AJ Jr, Kleensang A, Li H, Livi C, Maertens A, McMullen PD, Rosenberg M, Thomas R, Vantangoli M, Yager JD, Zhao L, Hartung T.
ALTEX. 2015;32(2):112-24. doi: 10.14573/altex.1502091

Related information